HRMY — Harmony Biosciences Holdings, I

Is HRMY overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Harmony Biosciences Holdings, I (HRMY) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $32.96. The rating moved from Neutral to Oversold on November 16, 2026.

See all oversold Healthcare stocks →

AI analysis

Harmony Biosciences Holdings, I (HRMY) is a specialty biopharma whose near-term financial profile is driven primarily by sales of its commercial sleep-disorder product. Growth prospects hinge on continued prescriber adoption, broader payer coverage, and successful international or label-expansion initiatives. The company benefits from established clinical differentiation in its niche but remains exposed to single-product concentration, competitive therapies, and reimbursement pressure. In the current market environment—characterized by cautious risk-on positioning and focus on policy signals—HRMY may see modest trading support, but medium-term upside depends on execution on commercialization and expanding the product portfolio or strategic partnerships. Key scenarios include steady organic growth if uptake and payor agreements improve, or below-expectation results if competitors or coverage issues constrain demand.

Key factors

  • Revenue concentration around a single commercial product (pitolisant/WAKIX) with established indications for narcolepsy-related excessive daytime sleepiness and cataplexy
  • Clear commercial footprint with prescriber familiarity in sleep medicine; continued uptake and payer coverage expansion are primary drivers of near-term sales growth
  • Opportunity for label expansion, international launches and line extensions to broaden addressable market and extend revenue runway
  • Favorable near-term market tone focused on policy clarity rather than risk-off selling, which can support small- and mid-cap biotech sentiment in the short run
  • Strategic optionality from partnering/licensing or M&A interest from larger pharma seeking specialty franchise exposure

Risks

  • Single-product dependency creates binary financial outcomes if uptake slows, reimbursement deteriorates, or sales plateau
  • Competition from alternative narcolepsy therapies (including stimulants, solriamfetol, and sodium oxybate formulations) that can limit market share and pricing power
  • Payer pressure and reimbursement challenges that could compress realized pricing or restrict patient access
  • Regulatory and patent risk (including potential generic entrants or unfavorable label actions) that could materially impact long-term revenues
  • Execution risk around international commercialization, managed care contracting, and salesforce scalability given limited product portfolio and resources
  • Macro/market volatility tied to monetary policy that could reduce investor appetite for specialty small-caps despite a measured near-term tone

See today's live rating, score and targets

Members see the live hourly rating for HRMY — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.